RecruitingNCT02432560
Safety and Durability of Sirolimus for Treatment of LAM
Studying Lymphangioleiomyomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Cincinnati
- Principal Investigator
- Francis X McCormack, MDUniversity of Cincinnati
- Intervention
- Sirolimus(drug)
- Enrollment
- 600 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2015 – 2025
Study locations (20)
- Stanford University Medical Center, Stanford, California, United States
- National Jewish Health, Denver, Colorado, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- Loyola University Medical Center, Chicago, Maywood, Illinois, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University of Rochester Medical Center, Rochester, New York, United States
- University of Cincinnati, Cincinnati, Ohio, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Oregon Health and Science University, Portland, Oregon, United States
- University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- +5 more locations on ClinicalTrials.gov
Collaborators
Rare Diseases Clinical Research Network · National Institutes of Health (NIH) · National Heart, Lung, and Blood Institute (NHLBI) · The LAM Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02432560 on ClinicalTrials.govOther trials for Lymphangioleiomyomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06889168Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)Columbia University
- RECRUITINGPHASE4NCT07138144Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-UpJosé Antonio Mata Marín
- RECRUITINGNANCT07304856Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis ComplexUniversity of Milan
- ACTIVE NOT RECRUITINGPHASE2NCT06519357A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- RECRUITINGNANCT06405997The Genotype and Phenotype of LymphangioleiomyomatosisNational Taiwan University Hospital
- RECRUITINGPHASE4NCT06907056Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in MexicoJosé Antonio Mata Marín
- ENROLLING BY INVITATIONNCT05727852Breath Analysis and Arterial Stiffness in Patients With Respiratory DiseasesI.M. Sechenov First Moscow State Medical University
- ACTIVE NOT RECRUITINGPHASE1NCT05467397Feasibility of [11C]Acetate-PET in LAM and TSCBrigham and Women's Hospital